Thymosin Alpha-1

Based on the available evidence, the safety profile of thymosin alpha-1 (thymalfasin) appears favorable, though comprehensive safety data is limited in the provided studies.

Known Side Effects

The evidence regarding specific side effects is thin. One recent retrospective study in non-small cell lung cancer patients receiving thymalfasin combined with immune checkpoint inhibitors reported "favorable safety," but detailed adverse event profiles were not provided in the available abstracts. A phase II trial combining spatially fractionated radiotherapy with immunotherapy (potentially including thymosin alpha-1) reported "favorable safety" with "early evidence of promising efficacy," but specific safety data were not detailed.

Evidence limitation: The provided studies focus primarily on efficacy outcomes rather than comprehensive safety reporting, making it difficult to establish a complete adverse effect profile.

Contraindications

No specific contraindications are identified in the available evidence. However, given thymosin alpha-1's immunomodulatory effects, caution would theoretically be warranted in patients with autoimmune conditions, though this is not explicitly documented in the provided studies.

Drug Interactions

The evidence shows thymosin alpha-1 has been studied in combination with:

• Immune checkpoint inhibitors (reported as safe in combination)
• Conventional chemotherapy
• Radiotherapy
• IL-15 (in hepatocellular carcinoma studies)

No specific drug interactions or contraindicated combinations are reported in the available literature, though the evidence base for interaction assessment is limited.

Special Populations

Evidence is particularly thin regarding special populations. The studies provided do not contain specific safety data for:

• Pregnant or breastfeeding women
• Pediatric patients
• Elderly patients
• Patients with severe kidney or liver disease (beyond the hepatitis B context studied)

Several studies involved patients with hepatitis B-related liver conditions and hepatocellular carcinoma, suggesting potential safety in these populations, but comprehensive safety profiles for patients with severe hepatic impairment were not detailed.

Clinical Trial Safety Data

Multiple completed clinical trials (NCT01938820, NCT04963712, NCT00082082) have been conducted, suggesting regulatory acceptance of the safety profile, though detailed safety results from these trials are not provided in the available evidence.

Important note: This safety information is based on limited available evidence and should not replace consultation with a healthcare provider. Patients considering thymosin alpha-1 therapy should discuss their complete medical history and current medications with their physician to assess individual risk factors and appropriateness of treatment.